Carfilzomib price

Carfilzomib (Carfilzomib) is a drug mainly used to treat multiple myeloma (Multiple Myeloma) and other related blood cancers. Its mechanism of action is to interfere with the survival and proliferation of abnormally proliferated cancer cells by inhibiting the function of the proteasome.

Carfilzomib has been launched in China and is included in medical insurance. Patients can purchase it domestically at a price of around 8,000 to 9,000 yuan. Please consult the local hospital pharmacy for specific prices. In foreign countries, the original drug of carfilzomib is mainly available, and the cheaper version is the European version of the original drug, which costs around 5,000. And the medicinal ingredients and efficacy are the same as those of domestic original medicines.

Multiple myeloma is a malignancy in the leukemia and lymphoma systems in which plasma cells in the bone marrow proliferate abnormally, leading to damage to the skeletal system, production of abnormal proteins, and damage to the immune system. Carfilzomib stands out for its targeted mechanism of action. Unlike traditional chemotherapy drugs, it does not kill rapidly dividing cells with toxic effects, but rather kills these cancer cells by inhibiting protein degradation within the cancer cells.

Carfilzomib is usually given to patients as an intravenous injection to ensure precise delivery of the drug. The exact dosage and usage of the treatment plan will vary depending on the patient's condition, often requiring multiple cycles of treatment. Patients will need regular blood tests and monitoring during treatment to ensure the effectiveness of the treatment and minimize adverse effects.

Although carfilzomib has made significant progress in the treatment of multiple myeloma, patients should receive treatment under the supervision of a physician to ensure safety and effectiveness. Medications may be associated with side effects such as low platelets, heart problems, and abnormal kidney function, so doctors will monitor the patient's condition closely to adjust the treatment plan. Overall, carfilzomib represents an innovation in modern cancer treatment and has the potential to improve survival and quality of life of patients with multiple myeloma by precisely intervening in tumor growth mechanisms.